You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Related Community Videos on Diabetes Health TV
Children with Diabetes and Diabetes Awareness
First Look: New iPhone App for Logging Readings and Much More
Carol speaks about the Diabetes Health Box Program
Popular Novo Nordisk Articles
Highly Recommended Novo Nordisk Articles
A survey of type 1 and type 2 diabetes patients in the United States, United Kingdom, France, and Germany indicates that more than one in every five have arrived late at work or not shown up at all because of a hypoglycemic episode the night before.
0 comments - Feb 21, 2012 -
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.
0 comments - Feb 3, 2012 -
RALEIGH, NC- DiabetesSisters is pleased to announce that registration for the 2012 Weekend for Women Conference opened on January 1, 2012, at 8 AM. The conference, a revolutionary weekend designed specifically for women with diabetes, will take place Friday, May 18, through Sunday, May 20, 2012, at the Marriott City Center in downtown Raleigh.
0 comments - Jan 24, 2012 -
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)
0 comments - Dec 15, 2011 -
A brand new insulin will soon be on pharmacy shelves in the United States if Danish pharmaceutical company Novo Nordisk has its way. The company has filed for approval from the Food and Drug Administration to sell insulin degludec, an original formulation that lasts an extra-long time. Insulin degludec is injected only once a day. Once under the skin, the dose of insulin is absorbed slowly and consistently, allowing for better nighttime control, according to Novo. Most importantly, test subjects had a low rate of hypoglycemia on the drug.
0 comments - Oct 15, 2011 -
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.
0 comments - Oct 2, 2011 -
Being a rookie driver on the fast-paced IndyCar racing circuit is pressure enough for any 26-year-old. But for Charlie Kimball, one of four wheel men on businessman Chip Ganassi's IndyCar race team, there's the added need to manage type 1 diabetes while roaring around the track at speeds that often exceed 200 miles per hour.
0 comments - Sep 25, 2011 -
Victoza, a drug aimed at type 2 diabetes, may turn out to be a boon for type 1 diabetes patients as well. A small clinical study shows that patients with well-controlled type 1 who took Victoza daily for just one week experienced a 15 percent drop in their blood sugar levels. Patients who took the drug over a full 24-week test period needed less and less insulin, decreasing their average mealtime dose by seven units and their all-day insulin requirement by eight.
0 comments - Jul 11, 2011 -
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
0 comments - May 23, 2011 -
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.